16dd072b-b664-43e8-8862-c9d9d945f8bc
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.500
- PROTEIN_SECRETION+0.400
- ADIPOGENESIS+0.300
- GLYCOLYSIS+0.300
- HYPOXIA+0.300
- INTERFERON_ALPHA_RESPONSE+0.300
- MTORC1_SIGNALING+0.300
- PEROXISOME+0.300
- ANDROGEN_RESPONSE+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- APICAL_SURFACE-0.300
- COAGULATION-0.300
- INFLAMMATORY_RESPONSE-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- COMPLEMENT-0.200
- IL2_STAT5_SIGNALING-0.200
- IL6_JAK_STAT3_SIGNALING-0.200
- KRAS_SIGNALING_DN-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG570 | — | — | 0.801 |
| 2 | BS_KSKZ9J7J | Embryonal tumors | — | 0.755 |
| 3 | SRR23303753 | — | — | 0.749 |
| 4 | SRR13311183 | — | — | 0.746 |
| 5 | TCGA-A8-A09N-01A-11R-A00Z-07 | — | B | 0.745 |
| 6 | R408 | — | — | 0.739 |
| 7 | R414 | — | — | 0.719 |
| 8 | MNG168 | — | — | 0.713 |
| 9 | SRR1797299 | — | cohortSC | 0.712 |
| 10 | SJEPD030833_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.712 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |